Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.
Lars Erik KristensenKhai Jing NgMarcus NgantchaJacques MorelEnnio LubranoWilliam TillettRieke E AltenVinod ChandranÀngels Martinez FerrerBaojin ZhuDominika KennedyThorsten HolzkämperNicola J GullickAndris KronbergsWalid FakhouriInmaculada de la TorreDennis G McGonaglePublished in: RMD open (2024)
This study confirms the rapid 3-month effectiveness of IXE on joint disease activity-as fast as TNFi and JAKi (cDAPSA), and exceeding IL-12/23i and IL-23i-along with clear benefits to skin.